Gilead Sciences, Inc. GILD
150.93
1.24
0.83%
as of 25 Sep
- Market cap
- $183.2B
- P/E
- 0.0×
Follow GILD
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
40.71% | 40.66% | 43.36% | (20.68%) | |
| 14.35% | 14.42% | 16.35% | (6.17%) | ||
ROIC |
16.79% | 15.69% | 17.07% | (4.48%) | |
Return on Tangible Assets |
73.22% | 70.13% | 62.26% | (36.99%) | |
Average Days of Receivables |
63.93 | 60.91 | 58.19 | 60.58 | |
Free Cash Flow per Share |
7.37 | 7.60 | 8.24 | 10.41 | |
Free Cash Flow |
9,162.00 | 9,456.00 | 10,230.00 | 12,943.00 | |
Capital Expenditures |
(505.00) | (563.00) | (576.00) | (609.00) | |
Piotroski F-Score |
8.00 | 7.00 | 8.00 | 4.00 | |
| Other line items | |||||
Cash ROIC |
17.99% | 18.15% | 20.29% | 32.92% | |
Accounts Receivable Turnover |
6.01 | 6.31 | 6.51 | 6.19 | |
Accounts Payable Turnover |
7.24 | 8.05 | 8.88 | 9.90 | |
Inventory Turnover |
3.39 | 3.58 | 3.34 | 3.29 | |
Average Days of Payables |
47.64 | 41.86 | 38.35 | 39.57 | |
Days of Inventory on Hand |
105.24 | 103.87 | 113.80 | 114.66 | |
Tax Rate |
(0.18) | (0.13) | (0.14) | 0.66 | |
Research and Development Expense of Revenue |
20.14% | 19.70% | 19.48% | 19.91% | |
Selling, General and Administrative Expense of Revenue |
20.24% | 19.61% | 20.07% | 21.42% | |
Share Based Compensation of Revenue |
3.05% | 3.04% | 3.04% | 2.98% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.19 | 1.18 | 1.17 | (4.18) | |
Depreciation/Fixed assets |
0.50 | 0.49 | 0.49 | 0.47 | |
Capex/Depreciation |
(0.18) | (0.20) | (0.21) | (0.22) | |
Revenue per Share |
23.40 | 23.67 | 23.94 | 24.50 | |
Operating CF per Share |
7.78 | 8.05 | 8.70 | 10.90 | |
Capex per Share |
(0.41) | (0.45) | (0.46) | (0.49) | |
Capex to Sales |
0.02 | 0.02 | 0.02 | 0.02 | |
Net Profit Margin |
27.88% | 28.90% | 30.99% | (10.64%) |
Columns are period end dates